Alvotech
Manufacturing · Iceland · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
15-19 Saemundargata, Reykjavik, Capital ...Phone Number
+354 4224500Website
www.alvotech.comRevenue
$586.3 MillionStock Symbol
ALVOIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
3
1
1
1
1
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patientsRead more
Alvotech Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alvotech your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Alvotech has recently received funding, and reach out quickly before it becomes old news!
Check out if Alvotech is spiking on competitors!
Funding: Get notified immidiatlly once Alvotech has new funding data
Click to see if Alvotech had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Alvotech, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Alvotech
Product Launch: Get notified when Alvotech launches new products
Earning: See what the market has to say on Alvotech recently announced quarterly report
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Alvotech
Find 2 more new buyers
Company Profile Activity
Activity Insights
Alvotech is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Alvotech is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Alvotech.
Alvotech financials insights
Gather financial insights about Alvotech, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Other Financing Round
$300M
2021
Share Placement
$35M
2022
Multiple Rounds
$136M
2023
Debt
$100M
2026
Debt
$117.2M
Alvotech Tech Stack
A closer look at the technologies used by Alvotech
Most Recent Scoops
Open Position
Person-Based
Compliance, Pharmaceuticals
Person-Based
Finance, Investor Relations
Person-Based
Earnings, Finance, Investor Relations
Person-Based
Clinical Operations
Alvotech News & Media
Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement
REYKJAVIK, ICELAND (June 16, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of 22,666,667 of its ordinary shares at an offering price of $3.75 per share. All ordinary shares to be sold in the Offering will be offered by Alvotech. The Offering isAlvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares
REYKJAVIK, Iceland, June 15, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has commenced an underwritten public offering of its ordinary shares (the “Offering”). In addition, Alvotech expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares sold in theAlvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares
REYKJAVIK, ICELAND (June 15, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has commenced an underwritten public offering of its ordinary shares (the “Offering”). In addition, Alvotech expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares sold in the public offering aAlvotech Hits Critical Inflection as Biosimilar Pipeline Nears FDA Decisions
Alvotech (NASDAQ:ALVO) Chief Strategy Officer Balaji Prasad said the biosimilars-focused company is entering a “critical inflection period” as it advances several limited-competition products through regulatory review and prepares for a broader launch cycle over the next several years. Speaking dur
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Alvotech
Sign Up For FreeTo access detailed company insights
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditio... Read More
